97O * EGFR MUTANT SUBSET ANALYSIS FROM ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF DACOMITINIB VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Paz-Ares, L., O'Byrne, K., Mok, T. S. K., Boyer, M., Janne, P. A., Goldberg, Z., Mather, C., Taylor, I., Zhang, H., Ramalingam, S. S.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv050.02
Date:
April, 2015
File:
PDF, 33 KB
english, 2015
File converter
More search results
More benefits 
